A Case of Curative Resection of Advanced Combined Hepatocellular-cholangiocarcinoma after Neoadjuvant Chemotherapy.
10.15279/kpba.2016.21.2.101
- Author:
Jee Eun CHOI
1
;
Kyung Hee KIM
;
Seon A KIM
;
Jung Hwan LEE
;
Sang Myung WOO
;
Sang Jae PARK
;
Eun Kyung HONG
;
Woo Jin LEE
Author Information
1. Pancreaticobiliary Cancer Clinic, Center for Liver Cancer, National Cancer Center, Goyang, Korea. lwj@ncc.re.kr
- Publication Type:Case Report
- Keywords:
Combined hepatocellular-cholangiocarcinoma;
Neoadjuvant chemotherapy;
Curative resection
- MeSH:
Cholangiocarcinoma;
Cisplatin;
Diagnosis;
Drug Therapy*;
Follow-Up Studies;
Humans;
Liver Neoplasms;
Neoadjuvant Therapy;
Recurrence;
Stem Cells
- From:Korean Journal of Pancreas and Biliary Tract
2016;21(2):101-106
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Combined hepatocellular-cholangiocarcinoma (HCC-CC) is a primary liver cancer with histopathologic features of both hepatocelluar carcinoma and cholangiocarcinoma. As combined HCC-CC has been associated with poor outcomes, accurate diagnosis and proper treatment planning for patients are considered to be important for improving survival. Currently, surgery is known as the only treatment modality offering potential cure for localized disease. However, there are little published treatment options for advanced or recurrent disease. Furthermore, no published reports exist in respect to the applying successful curative resection after neoadjuvant therapy for advanced combined HCC-CC. Here, we report a case of combined HCC-CC subtype with stem cell feature, intermediate type who underwent curative surgical resection after neoadjuvant chemotherapy consisting of cisplatin and gemcitabine. Pathologic report revealed negative resection margin and follow-up imaging study shows no evidence of tumor recurrence.
